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Case report Malignant fibrous histiocytoma of the distal femur 
after an arthroscopic anterior cruciate ligament 
reconstruction: A case report and a review of the 
literature
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Abstract
Background: Malignant degeneration in association with orthopaedic implants is a known but rare complication. To 
our knowledge, no case of osseous malignant fibrous histiocytoma after anterior cruciate ligament reconstruction is 
reported in the literature.
Case presentation: We report a 29-year-old male Turkish patient who presented with severe pain in the operated 
knee joint 40 months after arthroscopic anterior cruciate ligament reconstruction. X-ray and MR imaging showed a 
large destructive tumor in the medial femoral condyle. Biopsy determined a malignant fibrous histiocytoma. After 
neoadjuvant chemotherapy, wide tumor resection and distal femur reconstruction with a silver-coated non-cemented 
tumor knee joint prosthesis was performed. Adjuvant chemotherapy was continued according to the EURAMOS 1 
protocol.
Conclusions: Though secondary malignant degeneration after orthopaedic implants or prostheses is not very likely, 
the attending physician should take this into consideration, especially if symptoms worsen severely over a short period 
of time.
Background
The continuous increase in recreational sports leads to a
continuously increasing number of capsule and ligament
injuries of the knee joint as well. About 20% of the knee
injuries are accompanied by anterior cruciate ligament
(ACL) ruptures [1]. Reconstruction of the ACL belongs to
the therapies of choice for the sportively active patient
and is one of the most common surgical interventions for
knee ligament reconstruction [2].
The primary malignant fibrous histiocytoma (MFH)
has been described for the first time as a soft tissue tumor
in 1964 by O'Brien and Stout [3]. MFH occurs only rarely
as primary bone tumor and appears mainly on the meta-
and diaphysis of the long bones [4]. MFH usually occurs
in older age with a peak in the 6th decade of life; men are
affected more often than women [5]. The development of
secondary osseous malignant fibrous histiocytoma in
association with orthopaedic implants [6] or prostheses
[7] is a rare but nevertheless a known complication. Sec-
ondary malignant fibrous histiocytoma has been desribed
at sites of pre-existing bone lesions [8], after irradiation
treatment [9] and burn injuries [10].
In the case history presented below, we report the man-
ifestation of an osseous MFH at the distal femur 40
months after arthroscopic anterior cruciate ligament
reconstruction using autologous semitendinosus tendon.
To our knowledge, no case of an osseous MFH after ante-
rior cruciate ligament reconstruction is reported in the
literature.
Case presentation
In January 2006, a 26-year-old male had sustained an iso-
lated rupture of the right cruciate ligament during a soc-
cer game. This was diagnosed by a stability investigation
with a positive Lachman and Pivot shift test and was con-
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firmed by MRI. The knee joint was without signs of irrita-
tion. ROM was 0°-140°. Ten days later, arthroscopic ACL
reconstruction was performed using a quadruple autolo-
gous ipsilateral semitendinosus tendon graft. The fixation
elements used were a titanium Endobutton (Smith &
Nephew, Schenefeld, Germany) on the femoral side and a
titanium Suture Disc (B. Braun, Aesculap AG, Tuttlingen,
Germany) on the tibial side, respectively. The peri- and
postsurgical course was free of complications. 10 months
after ligament reconstruction, the patient could resume
sports activity and was very satisfied with the operative
outcome. 40 months after surgery, the patient presented
with strongly increasing pain in the medial femoral con-
dyle of the operated knee joint. Clinical investigation
showed a stable knee without signs of soft tissue irrita-
tion. Non-contrast radiology showed a space-occupying
lesion of 5.6 × 5 cm at the medial femoral condyle, mainly
located in the metaphysis (Figure 1a and 1b). The margins
showed partly a sclerotic zone and partly an infiltrating
margin. There was no obvious soft tissue shadow.
MRI with contrast agent (Gadolinium) revealed a bone
tumor of 6.2 × 5 × 4.2 cm. The bone tumor had infiltrated
the medial retinaculum and the vastus medialis muscle
(Figure 2a and 2b). Computertomographic staging inves-
tigation did not show any intrathorakal and intra-abdom-
inal metastases. Three-phase skeletal scintigraphy with
intravenous injection of 669.5 MBq Tc-99 m HDP did not
show any further pathological lesions, except from the
lesion at the right medial femoral condyle with increased
accumulation in the early and late phase. For diagnosis of
the tumor entity, an open biopsy of the space-occupying
lesion was performed. The tumor was a highly cellular
malignant mesenchymal tumor. It was composed of spin-
dle cells mainly. Areas of necrosis, increased vascularity
and CD68 positive histocytes (Figure 3a) were seen. Due
to its storiform growth pattern, moderate nuclear pleo-
morphy, strongly enhanced proliferative activity and
immunohistochemical marker profile, it was classified as
high-grade fibrous histiocytoma (Figure 3b and 3c). The
strong positive immune reaction against smooth muscle
actin antibodies did not support the possibility of a fibro-
sarcoma of the bone. Differential diagnosis of a leiomyo-
sarcoma of the bone had to be taken into account, but
this was less likely because the tumor was negative for
desmin and myogenin. After presenting the patient in the
Figure 1 Conventional X-ray imaging in anteroposterior (a) and 
lateral (b) projection show a 5.6 × 5 cm osteolysis of the medial 
femoral condyle with infiltration into surrounding soft tissue af-
ter arthroscopic anterior cruciate ligament reconstruction using 
the semitendinosus tendon.
Figure 2 Coronary (a) and transversally (b) T1-weighted MRI se-
quence shows a bone tumor spreading across the medial cortical 
bone and infiltrating into the vastus medialis muscle and the me-
dial retinaculum. The graft and the femoral drill tunnel are not infil-
trated by the MFH.
Figure 3 (a) shows the tumor biopsy with CD68 positive histio-
cytes (black arrows, 200-fold magnification), (b) shows the histo-
logical picture of a cell-rich mesenchymal tumor with storiform 
growth pattern, marked polymorphism, high rate of mitosis 
(black arrows) and marked angioneogenesis (*); HE, 200-fold 
magnification. (c) demonstrates the clear sm actin immunoreactiv-
ity (black arrow) of the tumor cells; anti-sm actin, 100-fold magnifica-
tion.
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interdisciplinary tumor conference, he was included into
the osteosarcoma register (Prof. Bielack, Olgahospital
Stuttgart, Germany). 2 chemotherapy cycles were per-
formed over a 10 week period according to the EURA-
MOS 1 protocol.
An en bloc-resection of the distal femur 12 cm proxi-
mal to the knee joint including adjacent joint capsule and
tumor-infiltrated soft tissue was performed. Resection
was performed 1.5 cm below the tibial plateau. For subse-
quent distal femur reconstruction, a silver-coated non-
cemented modular knee joint prosthesis (MUTARS,
Implantcast, Buxtehude, Germany) was used (Figure. 4a
and 4b). On the medial side, covering of soft-tissue
defects with a flap was unnecessary. Postoperative mobil-
isation was conducted under partial weight bearing of 15
kg using 2 forearm crutches for the period of six weeks.
The peri- and postsurgical course was regular and free of
complications. Macroscopic pathological assessment
showed a brown glassy tumor of up to 4.8 cm in size with
a centre at the medial femoral condyle (Figure 5). The
tumor reached the subchondral region. The distance
from tumor to proximal bone resection margin was 6.5
cm, to proximal soft tissue resection margin 5.2 cm, to
distal soft tissue resection margin 3 cm, to ventral soft tis-
sue resection margin 2.5 cm and to dorsal soft tissue mar-
gin 3.5 cm. The tibial plateau was tumor-free.
Histological examination of the specimen showed the
proven malignant fibrous histiocytoma which had been
completey resected. The site of semitendinosus tendon
graft insertion showed a bone with strong trabeculae.
Starting from the graft tunnel, collagen fibres (Sharpey-
like Fibers) that attached the tendon graft tightly to the
bone [11] could be demonstrated up to about 1.2 cm into
the surrounding bone (Figure 6a). The moderately regres-
sive MFH matching grade IV of Salzer-Kuntschik classifi-
cation [12] indicated an only moderate response to
neoadjuvant chemotherapy (Figure 6b). It was therefore
decided by the interdisciplinary tumor conference
together with the osteosarcoma register to carry on adju-
vant chemotherapy according to the EURAMOS 1 proto-
col. 6 months after the implantation of the tumor-
prosthesis the patient presented in our clinic. The post-
surgical course was still free of complications and the
patient was satisfied.
Figure 4 Conventional X-ray imaging in anteroposterior (a) and 
lateral (b) projection after the implantation of a silver-coated 
non-cemented modular knee joint prosthesis (MUTARS).
Figure 5 Saggital section at the medial femoral condyle. It shows 
the presence of an intraosseous tumor of up to 4.8 cm in size (black ar-
row) with brown, partially myxoid cut surface.
Figure 6 (a) Histology of the resected tumor still shows good vas-
cularisation (*) and moderate regression of the tumor tissue with 
about 25% vital cells (black arrows) after neoadjuvant therapy; 
HE, 100-fold magnification. (b) Strong trabeculae (*) and collagen fi-
bres (Sharpey-like Fibers; black arrows) that attached the tendon 
graft tightly to the bone; HE, 50-fold magnification.
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Conclusions
Osseous malignant fibrous histiocytoma has been
described for the first time in 1972 by Feldman and Nor-
man [13]. Its defined pathohistological characteristics
allow the distinction from other primary malignant bone
tumors. Among the primary malignant bone tumors,
MFH belongs to the rare ones with less than 5%. Since
several decades, endoprostheses and orthopaedic
implants have been used very successfully for treatment
of degenerative diseases and traumatic injuries. The com-
ponents of the used materials are considered as biologi-
cally inert.
In the literature, only 2 cases of malignant degeneration
after ACL have been described so far. Sirveaux et al. [14]
reported a 19-year-old male patient who underwent
arthroscopic anterior cruciate ligament reconstruction
using the patellar tendon in 1993. Tibial and femoral graft
fixation was performed using a metal interference screw.
6 years after surgery, a pleomorphic malignant fibrous
histiocytoma of the medial soft tissue was diagnosed at
the operated knee joint. Because suture and metal parti-
cles were found in the sarcoma, the authors suspected a
connection between the metal interference screws or the
drilling of the graft tunnels, respectively, and the emer-
gence of malignant fibrous histiocytoma. Caron et al. [15]
reported a leiomyosarcoma at the distal femur 12 years
after anterior cruciate ligament reconstruction. Also in
this case a joint adjacent fixation with a metal interfer-
ence screw had been performed. The sarcoma was
located close to the interference screws. The authors con-
s i d e r  i t  t o  b e  v e r y  u n l i k e l y  t h a t  t h e r e  i s  a  c o n n e c t i o n
between the malignant degeneration and the interference
screw fixation, as the fixation material was not at the
midpoint of the leiomyosarcoma. In the present case his-
tory, a fixation distant to the joint line with Endobutton
and Suture Disc was used. The MFH was localised in the
medial femoral condyle, far from the femoral drill tunnel.
In the MFH, suture or metal particles could not be
detected. A causal relationship between the Endobutton
and the development of malignancy is most unlikely, as
the Endobutton was positioned rather far from the MFH.
If a former trauma can favour MFH development
remains unclear. Bader et al. [16] reported a 14-year-old
girl who underwent plate osteosynthesis because of
supracondylar femur fracture. 10 months after metal
removal, a refracture and detection of an MFH at the
same location occured. In a different case, Joss et al. [17]
reported a 25-year-old patient with post-traumatic soft
tissue MFH at the elbow after a severe elbow contusion.
Both authors see a connection between the initial trauma
and MFH development. In the present case history, the
question cannot be clarified wether the MFH is a primary
one or if there is an association with the initial trauma.
However, regarding the latency period between initial
trauma and appearance of pain, we consider a connection
to be unlikely. By reanalysing the MR images taken in
2005, MFH presence prior to anterior cruciate ligament
reconstruction could be excluded (Figure 7).
As the five-year survival rate is 10 to 30% if the MFH is
treated only locally, neoadjuvant and adjuvant chemo-
therapy was performed analogous to the treatment of
osteosarcoma in several studies [18]. The multi-modal
therapy raised the five-year survival rate to 60%. Radio-
therapy has only limited effectiveness in the treatment of
highly malignant sarcomas and should only be applied if
the tumor cannot be removed surgically. In the present
case 2 cycles of chemotherapy were performed 10 weeks
preoperatively, using adriamycin, doxorubicin, cisplatin
and high dose-methotrexate with folic acid rescue. Under
neoadjuvant chemotherapy, the MFH showed only mod-
erate regressive changes (10 -- 50% vital tumor cells). The
pain, however, had completely disappeared between neo-
adjuvant chemotherapy and surgical removal of the
tumor.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
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Figure 7 Coronary MRI sequence. Non-appearance of MFH before 
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